2,867 Shares in The Clorox Company (NYSE:CLX) Purchased by Roman Butler Fullerton & Co.

Roman Butler Fullerton & Co. purchased a new stake in shares of The Clorox Company (NYSE:CLX - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund purchased 2,867 shares of the company's stock, valued at approximately $400,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Integral Investment Advisors Inc. grew its position in Clorox by 4.1% in the 4th quarter. Integral Investment Advisors Inc. now owns 1,718 shares of the company's stock worth $279,000 after purchasing an additional 67 shares in the last quarter. Sonora Investment Management Group LLC lifted its holdings in Clorox by 2.5% during the first quarter. Sonora Investment Management Group LLC now owns 2,940 shares of the company's stock worth $433,000 after acquiring an additional 72 shares during the period. Sound View Wealth Advisors Group LLC boosted its position in Clorox by 6.1% in the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,345 shares of the company's stock worth $218,000 after purchasing an additional 77 shares during the last quarter. Wedbush Securities Inc. grew its stake in Clorox by 1.2% in the 4th quarter. Wedbush Securities Inc. now owns 7,624 shares of the company's stock valued at $1,238,000 after purchasing an additional 94 shares during the period. Finally, Aviance Capital Partners LLC increased its position in shares of Clorox by 3.2% during the 4th quarter. Aviance Capital Partners LLC now owns 3,180 shares of the company's stock valued at $516,000 after purchasing an additional 100 shares during the last quarter. 78.53% of the stock is owned by institutional investors.

Clorox Price Performance

CLX stock opened at $122.12 on Wednesday. The firm has a market cap of $15.05 billion, a P/E ratio of 21.92, a P/E/G ratio of 2.80 and a beta of 0.54. The firm's fifty day moving average is $134.30 and its 200 day moving average is $147.74. The Clorox Company has a 52 week low of $121.98 and a 52 week high of $171.37. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.74 billion. Clorox had a net margin of 9.89% and a return on equity of 324.23%. The firm's quarterly revenue was down 8.0% compared to the same quarter last year. During the same period last year, the business posted $1.71 earnings per share. Research analysts predict that The Clorox Company will post 7.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Morgan Stanley lowered their price target on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their price target on Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. Barclays cut their price objective on Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a report on Wednesday, May 7th. Citigroup dropped their target price on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a research report on Monday, April 14th. Finally, UBS Group cut their price target on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $151.23.

Insider Buying and Selling

In other news, Director Pierre R. Breber purchased 4,000 shares of the business's stock in a transaction on Wednesday, May 7th. The shares were acquired at an average price of $136.57 per share, with a total value of $546,280.00. Following the acquisition, the director now directly owns 4,000 shares in the company, valued at approximately $546,280. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.57% of the stock is owned by corporate insiders.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.